MediWound Ltd. (MDWD)
NASDAQ: MDWDHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
MDWD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $165.90M
- EPS (TTM)
- -$2.12
- Dividend yield
- None
- 52-week range
- 12.52 – 20.03
- Day range
- 12.81 – 13.23
- Volume / Avg
- 72.43K / 84.20K
- Beta
- —
- Shares outstanding
- 12.91M
52-week range
MDWD stock today
On Oct 7, MDWD ended the session at $12.85, shedding $0.30 (2.28%), versus the S&P 500's 0.22% decline. At this level, MDWD sits near the bottom of its 52-week range of $12.52 to $20.03: 35.8% below the high, set on Oct 20, 2025 and 2.6% above the low. MDWD is down 30.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 26.7%.
MediWound has posted a net loss over the last twelve months (EPS of -$2.12), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About MediWound
Company profileMediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Ofer Gonen B.Sc.
- Headquarters
- Yavne
- Employees
- 121
- IPO year
- 2014
- Website
- mediwound.com
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$30.67+138.68%
- Strong buy 1
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
MediWound peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PEPGPepGen Inc. | 2.40 | +3.90% | $166.01M | vs MDWD |
| CUECue Biopharma Inc. | 22.51 | -2.72% | $163.52M | vs MDWD |
| NKTXNkarta Inc. | 2.27 | -1.73% | $162.59M | vs MDWD |
| VRXAVeraxa Biotech AG | 1.20 | +11.11% | $169.69M | vs MDWD |
| IPHAInnate Pharma S.A. ADS | 1.52 | -4.40% | $169.78M | vs MDWD |
| MSLESatellos Bioscience Inc. | 7.63 | +1.19% | $161.88M | vs MDWD |
| DTILPrecision BioSciences Inc. | 6.25 | +0.81% | $172.51M | vs MDWD |
| NBPNovaBridge Biosciences ADR | 1.37 | -2.14% | $158.92M | vs MDWD |
Indexes, lists and sector
Appears in lists
MediWound stock FAQ
What is MediWound's stock price today?
MDWD last traded at $12.85 as of Oct 7, 4:00 PM EDT, down 2.28% on the day. Prices are delayed at least 15 minutes.
Does MediWound pay a dividend?
No. MediWound does not currently pay a regular cash dividend.
Who is MediWound's CEO?
Mr. Ofer Gonen B.Sc. is the chief executive officer of MediWound Ltd., which has about 121 employees.
Has MDWD ever split its stock?
Yes. The most recent MDWD stock split was a 1-for-7 split on Dec 20, 2022.
What is the MDWD 52-week high?
The 52-week high for MDWD is $20.03 and the 52-week low is $12.52. The stock is currently 35.8% below its high.